Search

Displaying results 291 - 300 of 7655 in total
  1. Drug

    Cefepime

    go.drugbank.com/drugs/DB01413
    ApprovedInvestigational

    [A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as _Pseudomonas aeruginosa_, and is also indicated for the empirical

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Cefevon powder for solution for injection 2g/vial, ROXIPIME POWDER FOR SOLUTION FOR INJECTION 2G/VIAL
  2. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.

    Products: EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120 MG/ML, Pontevia 120 mg solution for injection in pre-filled pen
  3. Drug

    Lonoctocog alfa

    go.drugbank.com/drugs/DB13998
    ApprovedInvestigational

    Products: AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIAL
  4. Drug

    Pasireotide

    go.drugbank.com/drugs/DB06663
    ApprovedInvestigational

    It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

    Products: SIGNIFOR LAR(60 MG POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION), SIGNIFOR LAR POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 40MG
  5. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]

    Products: VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML, Vyepti® 100 mg/mL concentrate for solution for infusion
  6. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.

    Products: OPDIVO CONCENTRATE FOR SOLUTION FOR INFUSION 10 MG/ML, Opdivo 10mg/ml, Concentrate for solution for infusion
  7. Drug

    Lidocaine

    go.drugbank.com/drugs/DB00281
    ApprovedInvestigationalVet approved

    Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication [T583]. … In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety

    Mixtures: Careland Lidocaine 4 plus menthol pain relieving gel-patches with border for knee, Careland Lidocaine 4 Plus Menthol Pain Relieving Gel Patches for back, neck shoulders knees and elbows with borderCategories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Anesthetics for Topical Use
  8. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

    Products: BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL
  9. Drug

    Bortezomib

    go.drugbank.com/drugs/DB00188
    ApprovedInvestigational

    Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome ...

    Products: Retrox 3.5mg Powder for Solution for Injection, BORTESUN POWDER FOR SOLUTION FOR INJECTION 3.5 mg
  10. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]

    Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/MLProducts: LYXUMIA (SOLUTION FOR INJECTION 10 MCG), LYXUMIA (SOLUTION FOR INJECTION 20 MCG)